Procyon's Shareholders Approve Merger Via Acquisition with Cellpep S.A.
Procyon Biopharma Inc. announced that at its Special Meeting of Shareholders shareholders of Procyon approved the acquisition of Cellpep S.A. and the concurrent $18.1 million private placement of special warrants and units. The name change of Procyon Biopharma Inc. to Ambrilia Biopharma Inc. and the future share consolidation were also approved by Procyon' shareholders.
Following the closing of the acquisition and concurrent financing, which is expected on or about March 1, 2006, the name of Procyon Biopharma Inc. will be changed to Ambrilia Biopharma Inc. and its shares will continue to trade on the Toronto Stock Exchange under the new ticker symbol AMB.
The approved share consolidation within a range of five to ten would occur at a later date during the year, as it is the intention of the Company to consolidate its shares following an information campaign and the attainment of certain corporate milestones during the year 2006.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Antitope and Synthon announce collaboration
Analysis by AlgoNomics reveals that Anticalins have an immunogenicity level comparable to the wild-type human lipocalin
Cellectis Acquires Vectocell Technology to Accelerate Therapeutic Development Programs
New data for Menveo vaccine show excellent immune response and broad protection for infants against meningococcal meningitis - Menveo (MenACWY-CRM) the first quadrivalent conjugated meningitis vaccine to demonstrate an excellent immune response in infants
Kentucky Bioprocessing, Icon Genetics and Mapp Biopharmaceutical have entered into discussions to merge their businesses
